

Abstract

1. Introduction

 Dipeptidyl peptidase IV (DPP-IV; EC 3.4.14.5), a serine protease, has a specificity for removing dipeptides from the N-terminus of substrate peptides and proteins by cleaving postproline or alanine residues [1]. It is present in body fluids and a variety of tissues, including liver, kidney and small intestine, and exists as a soluble circulating form [2,3]. DPP-IV has been shown to degrade chemokines, neuropeptides and many hormones, such as glucagon-like peptide 1 (GLP-1) [4]. GLP-1 is an incretin hormone that has potential to induce insulin secretion from the islet β-cells in a glucose-dependent manner. GLP-1 has multifaceted actions, including glucose-induced stimulation of insulin biosynthesis and secretion, inhibition of glucagon secretion, glucose homeostasis, β-cell proliferation and survival, inhibition of food intake, and slowing of gastric emptying [5-7]. However, GLP-1 has a short half-life of only 1 to 2 min following secretion in response to the nutrients ingestion because of its degradation by DPP-IV [8]. The finding that over 95% of GLP-1 is degraded by the action of DPP-IV led to an elevated interest in inhibition of this enzyme for the treatment of type 2 diabetes [9]. Experiments in animals and humans have showed that specific DPP-IV inhibition increased the half-life of total circulating GLP-1, decreased plasma glucose, and improved impaired glucose tolerance [10-12]. There are some reports describing bioactive peptides possess DPP-IV inhibitory activity. Diprotin A and B, isolated from culture filtrates of *Bacillus cereus* BMF673-RF1, were found to exhibit the inhibitory activity on DPP-IV [13] and they were elucidated to be Ile-Pro-Ile and Val-Pro-Leu, respectively. A 73 bioactive peptide, Ile-Pro-Ala, prepared from β-lactoglobulin showed an IC₅₀ value

- 3 -

74 of 49 μM for DPP-IV *in vitro*; in the meanwhile, Diprotin A showed the IC₅₀ value of 7 μM *(14)*. Patent WO 2006/068480 and WO 2009/128713 have demonstrated that the peptides derived from milk and egg protein hydrolysates display DPP-IV inhibiting activity, and the peptides are in particular characterized by the presence of a proline within the sequence in the second N-terminal residue [5,15]. In our previous studies, we have successfully isolated 10 antioxidative 80 peptides from tuna cooking juice hydrolyzed by Protease XXIII and orientase; meanwhile, nine of the peptides comprised at least one proline residue [16,17]. In our preliminary test, the major amino acid compositions of tuna cooking juice were Gly, His, Ala, Glu and Pro; and further, the proline content was 27.1 μmol/mL cooking juice (data not shown). Therefore, the objective of the present study was to determine the DPP-IV inhibitory activities of tuna cooking juice hydrolyzed by Protease XXIII and orientase. Then the sequences of the DPP-IV inhibitory peptides were identified.

2. Materials and Methods

2.1 Sample preparation

 A canned tuna processor in Chiayi County (Taiwan) supplied the tuna cooking juice in which the protein content was 5.44%. The whole tuna fish (*Thunnus tonggol*) was cooked by steam (100-105℃) for 3-4 h, after which, the hot collected cooking juice was sealed in 400-mL polyethylene bags and then transferred to our laboratory immediately, and stored at 4℃ overnight. The cooking juice was filtrated through two layers of gauze to remove floating fats and solids, and the filtrate was collected and 97 stored at -30℃ within 30 days until used.

- 4 -

2.2 Chemicals and reagents

2.3 Enzymatic hydrolysis

 Twenty-five milliliter of cooking juice was preincubated at 50℃ for 20 min prior to enzymatic hydrolysis. The hydrolysis reaction was started by the addition of 25 or 50 mg proteases (1 or 2 mg/mL of cooking juice; enzyme/protein substrate ratio: 1.84 or 3.68%). The reactions with Protease XXIII (PR) and orientase (OR) were conducted at pH 7.5, 37℃ and pH 7.0, 50℃, respectively, for up to 6 h. The hydrolysates were heated in boiling water for 15 min to terminate hydrolysis and then centrifuged (Centrifuge 05P-21, Hitachi Ltd., Katsuda, Japan) at 10,000×g for 120 10 min. A part of the supernatant was collected to determine its degree of hydrolysis, and the other part was freeze-dried (FDU-540, EYELA freeze-dryer,

- 5 -

Tokyo, Japan) and stored in a desiccator for further purification.

2.4 Measurement of degree of hydrolysis

 DPP-IV activity determination in this study was performed in 96-well microplates by measuring the increase in absorbance at 385 nm using

- 6 -

 Gly-Pro-*p*-nitroanilide as DPP-IV substrate *(20)*. The lyophilized hydrolysates were dissolved in 100 mM Tris buffer (pH 8.0) at various concentrations. The hydrolysate solution (25 μL) was added with 25 μL of 1.59 mM Gly-Pro-*p*-nitroanilide (in 100 mM Tris buffer, pH 8.0). The mixture was incubated at 37℃ for 20 min, followed by the addition of 50 μL of DPP-IV (diluted with the same Tris buffer to 0.01 units/ml). The reaction mixture was incubated at 37℃ for up to 60 min, and the reaction was stopped every 5 min by adding 100 μL of 1 M sodium acetate buffer (pH 4.0). The absorbance of the resulting solution was measured at 385 nm with an ELISA reader (Bio Tek μ QUANT; Bio Tek Instruments, Inc., Winooski, VT, USA). Recorded data were plotted versus time, and the DPP-IV activity was quantified from the linear part of the curve. The % DPP-IV inhibition was defined as the percentage of DPP-IV activity inhibited by a 158 given concentration of hydrolysate (protein basis). The IC_{50} value corresponds to the concentration of sample needed to inhibit DPP-IV by 50%. Under the 160 conditions of the assay, IC_{50} values were determined by assaying appropriately diluted samples and plotting the DPP-IV inhibition rate as a function of the hydrolysate concentration.

- *2.6 Purification of DPP-IV inhibitory peptides*
- *2.6.1 Gel filtration chromatography*

 The DPP-IV inhibitory peptides of the hydrolysates were separated using column chromatography [21]. The lyophilized hydrolysates (50 mg) were dissolved

with 1 mL of deionized water. The resulting solution was fractionated by gel

filtration on a Sephadex G-25 column (2.5×50 cm, Pharmacia, Sweden), and eluted

- 7 -

The fractionated hydrolysates by gel filtration exhibiting DPP-IV inhibitory

activity were further purified using high performance liquid chromatography

(Model L-2130 HPLC, Hitachi Ltd., Katsuda, Japan). The lyophilized hydrolysate

fraction (100 μg) by gel filtration was dissolved in 1 mL of 0.1% trifluoroacetic

acid (TFA), and 90 μL of the mixture was then injected into a column (ZORBAX

Eclipse Plus C18, 4.6 × 250 mm, Agilent Tech. Inc., CA, USA) using a linear

gradient of acetonitrile (5 to 25% in 40 min) in 0.1% TFA under a flow rate of 0.7

mL/min. The peptides were detected at 215 nm. Each collected fraction was then

lyophilized and stored in a desiccator until use. A part of each lyophilized fraction

was redissolved in 100 mM Tris buffer (pH 8.0) at the concentration of 2 mg/mL to

- determine its DPP-IV inhibitory activity.
-

2.7 Identification of amino acid sequence by MALDI-TOF/TOF MS/MS

The purified peptides were analyzed by matrix-assisted laser desorption

ionization time-of-flight mass spectrometry (MALDI-TOF MS), using a delayed

- 8 -

- **3. Results**
- *3.1 Degree of hydrolysis during enzymatic hydrolysis*

The DH of tuna cooking juice hydrolyzed with PR and OR increased

dramatically during the initial 2 h and 1 h, respectively, and then increased

chromatography

 Fig. 3 shows the elution profiles and DPP-IV inhibitory activities of PR and OR enzymatic hydrolysates separated by gel filtration chromatography. Five

- 10 -

- fractions were collected from either PA and PR hydrolysates, respectively,
- separated by Sephadex G-25 gel (**Fig. 3**). The molecular weight (MW) distributions
- of fraction PR-1 (fraction no. 10-14), PR-2 (fraction no. 15-22), OR-1 (fraction no.
- 10-14) and OR-2 (fraction no. 15-21) were all over 1422 Da; while fraction PR-3
- (fraction no. 23-28), PR-4 (fraction no. 29-33), OR-3 (fraction no. 22-29) and
- OR-4 (fraction no. 30-35) showed the molecular size between 1422 and 753.9 Da.
- In addition, those of fraction PR-5 (fraction no. 34-57) and OR-5 (fraction no.
- 36-57) were between 753.9 and 204.2 Da. The fractions with the highest DPP-IV
- 250 inhibitory activity $(P \le 0.05)$ obtained from each enzymatic hydrolysates were
- PR-2 and OR-2, and they showed 39.5 and 38.8% of inhibition rate, respectively, at
- the concentration of 5 mg/mL. Therefore, the two fractions, PR-2 and OR-2, were
- used for further purification by HPLC.
-

3.4 Purification of DPP-IV inhibitory peptides by HPLC

 Fig. 4 shows the elution profiles and DPP-IV inhibitory activities of PR-2 and OR-2 separated by HPLC. To obtain a sufficient amount of purified peptide, chromatographic separations were performed repeatedly. The fraction PR-2 and OR-2 obtained from gel filtration chromatography were lyophilized and then 260 subjected to HPLC on a RP-C18 column $(4.6 \times 250 \text{ mm})$ with a linear gradient of acetonitrile (5-25%) containing 0.1% TFA. According to the elution profiles of both PR-2 and OR-2, only one major peak (the other one is the solution peak) was obtained at the retention time of about 4.8 min, and a lot of minor peaks were observed thereafter. Hence, we collected a fraction from the major peak and 4 fractions from the minor peaks every 7 minutes for both PR-2 and OR-2 (**Fig. 4**).

4. Discussion

 We reported three bioactive peptides derived from tuna cooking juice hydrolyzed by Protease XXIII and orientase which possess DPP-IV inhibitory activities. In the present study, the maximum cleavage of peptides occurred within 2 h and 1 h of PR and OR hydrolysis, respectively. The result was similar to our previous studies with tuna cooking juice and dark muscles (17,23). The DH values showed lower than those in our previous studies also with tuna cooking juice hydrolyzed by PR and OR (17,23) probably attributed to the addition of lower enzyme concentration in the present study.

 According to the reports in several patents (Patent WO 2006/068480 and WO 2009/128713), the DPP-IV inhibitory peptides have a length varying from 3-7 amino acids, and are generally characterized by a hydrophobic nature and in particular the presence of a proline residue within the peptide sequence. The proline residue is as the first or second N-terminal residue, and is also found as C-terminal or penultimate C-terminal residue. In the present study, all the three peptides comprised at least one proline residue in the sequence, and two peptides had the proline as the first N-terminal residue. Moreover, all the three peptides were composed of many hydrophobic amino acid residues, such as Val, Leu, Ile, Trp, Phe and Cys. Two peptides had Ala as the penultimate N-terminal residue as well as GLP-1, the substrate of DPP-IV *in vivo* [15,24]. However, the three peptides obtained in this study comprised 13-15 amino acid residues which were much longer than the preferable DPP-IV inhibitory peptides. Some peptides, Ile-Pro-Ala, Val-Ala-Gly-Thr-Trp-Tyr, Gly-Pro-Phe-Pro and Pro-Leu-Leu-Gln, comprised 3-7 amino acid residues as the preferable DPP-IV inhibitors showed 313 diverse IC₅₀ values against DPP-IV ranging from 49 to 174 μ M [14,15,25]. The

- 14 -

- 15 -

- peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-35.
- [9] McIntosh CHS, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase
- IV inhibitors: how do they work as new antidiabetic agents. Regul Peptides
- 2005, 128:159-65.
- [10] Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition
- potentiates the insulinotropic effect of glucagon-like peptide 1 in the
- anesthetized pig. Diabetes 1998, 47:764-9.
- [11] Deacon CF, Nauck, MA, Meier J, Hücking K, Holst JJ. Degradation of
- endogenous and exogenous gastric inhibitory polypeptide in healthy and in
- type 2 diabeic subjects as revealed using a new assay for the intact peptide. J
- Clin Endocr Metab 2000, 85:3575-81.
- [12] Mitani H, Takimoto M, Hughes TE, Kimura M. Dipeptidyl peptidase IV
- inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study
- using a Fischer 344 rat substrain deficient in its enzyme activity. Jap J
- Pharmacol 2002, 88:442-50.
- [13] Umezawa H, Aoyagi T, Ogawa K, Naganawa H, Hamada M, Takeuchi T.

- 19 -

- and (b) MALDI-TOF/TOF MS/MS spectrum of the peptides from PR-2c and
- OR-2c.
-
- 431 **Fig. 6.** DPP-IV inhibition rate and the IC₅₀ value of the synthetic peptides
- identified in **Fig. 5** and Diprotin A.